A variant in SMOC2, inhibiting BMP signaling by competitively binding to BMPR1B, causes multiple epiphyseal dysplasia

Feng Long, Li Lin, Hongbiao Shi, Pengyu Li, Shaoqiang Guo, Yuer Ma, Yan Li, Shijun Wei, Fei Gao, Shang Gao, Meitian Wang, Ruonan Duan, Xiaojing Wang, Kun Yang, Liu Ai, Anran Wang, Xiaohong Chen, Wenjie Sun, Xi Li, Jiangxia Li, Qiji LiubioRxiv 2020 · DOI

TL;DR

Researchers have identified a novel genetic cause for Multiple Epiphyseal Dysplasia (MED), a skeletal disorder, by pinpointing a specific mutation in the SMOC2 gene. This mutation disrupts BMP signaling by altering how SMOC2 interacts with BMP receptors, offering new insights into skeletal development and potential therapeutic targets.

What Problem Does This Paper Address?

Multiple Epiphyseal Dysplasia (MED) is a group of genetic disorders characterized by skeletal abnormalities, particularly affecting the epiphyses of long bones. While several genes have been implicated, a significant portion of MED cases remain genetically unexplained. This study aims to identify novel genetic causes for MED and elucidate the underlying molecular mechanisms. Specifically, the authors investigate a Chinese family with a suspected autosomal dominant form of MED, seeking to uncover the genetic basis for their condition.

Methods

The researchers employed a multi-pronged approach:

  • Exome Sequencing: This was used to identify genetic variations in affected individuals from the family.
  • Sanger Sequencing: This standard technique was used to confirm the identified mutation and track its inheritance within the family.
  • Knock-in Mouse Model: A crucial step involved creating mice with the specific SMOC2 mutation identified in the family. This allowed for in vivo study of the mutation's effects on skeletal development and BMP signaling.
  • Histological Analysis: Hematoxylin and eosin (H&E) staining and transmission electron microscopy (TEM) were used to examine the morphology of growth plates and chondrocytes in both wild-type and mutant mice.
  • Immunohistochemistry and Western Blotting: These techniques were used to assess the levels of key proteins involved in BMP signaling (e.g., p-Smad1/5/9, Ihh, Bax, Bcl-2) in various tissues and cell types.
  • Solid Phase Binding Assay (SPB) and Co-immunoprecipitation (Co-IP): These biochemical methods were employed to investigate the binding interactions of SMOC2 (wild-type and mutant) with extracellular matrix proteins (like collagen IX, HSPG) and BMP receptors (BMPR1B).

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • SMOC2 as a Novel MED Gene: The study establishes SMOC2 as a new gene associated with MED, expanding the known genetic landscape of this disorder.
  • The p.Leu359Arg Mutation's Impact: The specific missense mutation (c.1076T>G, p.Leu359Arg) in the EC domain of SMOC2 is identified as the causative variant. This mutation is highly conserved across species, suggesting its critical functional role.
  • Disruption of BMP Signaling: The mutation leads to a significant reduction in BMP signaling, evidenced by decreased phosphorylation of SMAD1/5/9 in growth plates and chondrocytes.
  • Altered Matrix Interactions: Mutant SMOC2 shows reduced binding affinity to collagen IX and HSPG, which are crucial components of the cartilage extracellular matrix.
  • Competitive Binding to BMPR1B: The study proposes that SMOC2, particularly in its mutant form, acts as an antagonist of BMP signaling by competitively binding to BMP receptors, specifically BMPR1B, thereby preventing BMP from activating its downstream pathways.

Key Results

  • Family Study: A four-generation Chinese family with autosomal dominant MED was identified, with 8 affected individuals. Exome sequencing revealed a novel heterozygous missense mutation, c.1076T>G (p.Leu359Arg), in the SMOC2 gene in all affected family members.
  • Mouse Model Phenotype: Smoc2 knock-in mice exhibited short-limbed dwarfism and dysplastic tibial growth plates with disorganized chondrocytes. These mice showed reduced body length and limb bone lengths compared to wild-type littermates.
  • BMP Signaling Inhibition: Both wild-type and mutant SMOC2 were shown to inhibit BMP signaling. In mutant mice, there was decreased phosphorylation of SMAD1/5/9. In vitro experiments confirmed that overexpressed SMOC2 and mutant SMOC2 could block SMAD1/5/9 phosphorylation.
  • Binding Interactions: Mutant SMOC2 exhibited reduced binding to collagen IX and HSPG. Crucially, both wild-type and mutant SMOC2 were found to bind to BMPR1B, suggesting a competitive inhibition mechanism.

Limitations and Future Work

  • Detailed Mechanism of Matrix Interaction: While the study shows reduced binding of mutant SMOC2 to collagen IX and HSPG, the precise downstream consequences of this altered interaction on cartilage integrity and MED pathogenesis require further elucidation.
  • In Vivo vs. In Vitro Discrepancies: The paper notes that in contrast to previous findings, SMOC2 in their study could not antagonize BMP activity in the presence of a constitutively activated BMP receptor. This suggests a complex regulatory role for SMOC2 that may depend on specific cellular contexts or receptor states.
  • Therapeutic Potential: The identification of SMOC2 as a MED-causative gene and its role in BMP signaling opens avenues for future research into therapeutic strategies for MED and potentially other BMP-related skeletal disorders. Further investigation into how to modulate SMOC2-BMPR1B interactions could be beneficial.
  • Broader Implications: The authors suggest that understanding the molecular genetics and cell-matrix pathophysiology of MED could aid in diagnosis, prognosis, and treatment, and may also shed light on the mechanisms of more common conditions like osteoarthritis.

Summary updated

Abstract

Abstract Previously study showed that SMOC, a matricellular protein, inhibits BMP signaling downstream of its receptor via activation of mitogen-activated protein kinase (MAPK) signaling. In our study, exome sequencing revealed a missense mutation (c.1076T>G, p.Leu359Arg) in EC domain of SMOC2 in a Chinese family with multiple epiphyseal disease (MED). The pathogenicity of this SMOC2 variant was verified by Smoc2 L359R/L359R knock-in mice. Of note, decreasing phosphorylation of SMAD1/5/9 was detected in growth plates and primary chondrocytes from Smoc2 L359R/L359R mice. Furthermore, binding affinity of mutant SMOC2 with collagen IX and HSPG in the extracellular matrix of cartilage were reduced while binding affinity with BMPRIB was intact. In addition, in contrast to previously results, that SMOC2 cannot antagonize BMP activity in the presence of a constitutively activated BMP receptor. These results support that SMOC2 with p.Leu359Arg variant act as an antagonist of canonical BMP pathway by competitively binding with BMP receptors.
BibTeX
@misc{long2020variant,
  author = {Feng Long and Li Lin and Hongbiao Shi and Pengyu Li and Shaoqiang Guo and Yuer Ma and Yan Li and Shijun Wei and Fei Gao and Shang Gao and Meitian Wang and Ruonan Duan and Xiaojing Wang and Kun Yang and Liu Ai and Anran Wang and Xiaohong Chen and Wenjie Sun and Xi Li and Jiangxia Li and Qiji Liu},
  title = {{A variant in <i>SMOC2,</i> inhibiting BMP signaling by competitively binding to BMPR1B, causes multiple epiphyseal dysplasia}},
  year = {2020},
  doi = {10.1101/2020.01.27.921825},
  howpublished = {bioRxiv},
}
Figure